* If you want to update the article please login/register
"Our aim is to establish a community-based cohort and novel genomic science resource for determining the biological significance of ancestry-related genetic variation in African-Americans in Cardiovascular Disease (GENE-FORECAST :GENomics, Environmental FactORS, and the Social DEterminants of Cardiovascular Disease in African Americans STudy. " In addition, this article will allow our team to evaluate the working hypothesis that race-ancestry differences in the burden of cardiovascular disease reflects the presence of a specific interplay between African-Americans and the exposition of a variety of socioeconomic determinants and environmental causes that influence CVD in AA. Given the high prevalence of CVD among AA students, this strategy would produce a sample of normal individuals as well as a high number of AA with CVD risk factors such as obesity and hypertension that might be related to CVD's potential clinical signs and symptoms. g. In some instances, family members of the proband may also be encouraged to participate in these G2P studies to help determine the biological significance of these putative functional DNA variants of interest. e. g. , 1 CVD risk factors well established. The key outcome variables involve well established CVD phenotypes: 1 CVD risk factors e. g. "E. g. " says one peripheral immune cell phenotyping study. g" is included in the G2P callback visit protocol.
Source link: https://clinicaltrials.gov/ct2/show/NCT02055209
We hypothesize that different myositis phenotypes are triggered by different environmental conditions in genetically vulnerable individuals, as well as existing clinical, epidemiological, and genetic variations among phenotypes. These patients have an acute myositis onset in the spring of the year and are also susceptible to fevers, elevated white blood cell counts, arthritis, and interstitial lung disease. We'll explore the possibility that particular environmental exposures are related to the anti-synthetase syndrome in matched controls and in myositis patients without the anti-synthetase syndrome in collaboration with many centers. Compared to 150 controls without autoimmune disease patients with the anti-synthetase syndrome, with the same diagnoses in isolated cases; and 2 determine whether selected infectious agents are more prevalent in blood samples of recent-onset myositis patients with the anti-synthetase syndrome compared to isolated controls; and compare with 150 control subjects without the anti-synthetase syndrome; and 2 determine whether selected infectious agents are more prevalent in blood or compared to patients without.
Source link: https://clinicaltrials.gov/ct2/show/NCT01276470
"Therefore, we recommend a protocol that includes three complementary options in order to determine the environmental conditions associated with the growth of myositis in active duty military forces as well as an initial understanding of the potential mechanisms involved. " In the first step, we will investigate the risk factors in a case-control study of 300 patients who contracted myositis while on active service by comparing them to 1500 active duty military personnel without having been diagnosed with an autoimmune disease or persistent muscle disease. In the second case-control model, we'll try to determine environmental causes involved with myositis that has arisen in military service by comparing them to 150 similarly matched military personnel who have no autoimmune disease or persistent muscle disease. The global DNA methylation epigenetic shifts, microRNA, and mRNA profiles in peripheral blood and muscle tissue from 18 patients will be determined by a third laboratory investigation, with the effects of various environmental exposures on these parameters. These complementary approaches will aid in the understanding of environmental causes and potential mechanisms involved with the development of myositis in the military as well as providing insights into environmental risk factors that may also be relevant to non-military populations. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT01734369
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions